FDA names head of oncology office
Executive Summary
FDA Oncology Division Director Richard Pazdur will head the newly created Office of Oncology Drug Products, effective May 1. The agency announced Pazdur's appointment April 22, nine months after beginning a "national search" for a director (1"The Pink Sheet" July 26, 2004, p. 13). Pazdur has been director of the Oncology Drug Products Division within the Center for Drug Evaluation & Research since September 1999. The new office will consolidate drug, biologic and medical imaging reviews previously handled by three separate offices; the reshuffling is part of broader Office of New Drugs reorganization planned for July...
You may also be interested in...
FDA Oncology Drug Reviews Headed By Justice Under Revised Structure
Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs
FDA Drug Safety Overhaul Will Not Affect Oncologics, Office Director Says
Potential changes to FDA's safety review practices will not affect oncology therapies, Office of Oncology Drug Products Director Richard Pazdur said at the American Society of Clinical Oncology annual meeting in Orlando, Fla. May 14
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.